title: DES the year in review: controversies.
abstract: Drug-eluting stents (DES) have transformed interventional cardiology over the past decade. Whilst their efficacy has rarely been called into question, there have been concerns over the safety of the early devices, which has prompted the development of new coronary stents. Many of these new devices have entered clinical practice, however questions remain as to whether they offer the improvements in clinical outcomes that were originally anticipated. In addition, there is a debate whether the reported high efficacy of these devices enables percutaneous coronary intervention (PCI) to be performed in patient and lesion sub-groups previous entirely the domain of the cardiac surgeon. This review paper addresses these outstanding questions.
authors.affiliation: Department of Cardiology East Lancashire NHS Trust Blackburn, Lancashire, UK. scotgarg@hotmail.com
authors.forename: S
authors.initials: S
authors.lastname: Garg
authors.forename: C
authors.initials: C
authors.lastname: Bourantas
authors.forename: P W
authors.initials: PW
authors.lastname: Serruys
mesh_terms: D001672:Biocompatible Materials; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D015897:Comorbidity; D023903:Coronary Restenosis / Q000517:prevention & control; D023921:Coronary Stenosis / Q000601:surgery; D003328:Coronary Thrombosis / Q000188:drug therapy / Q000601:surgery; D048909:Diabetes Complications; D018572:Disease-Free Survival; D054855:Drug-Eluting Stents / Q000009:adverse effects / Q000706:statistics & numerical data / Q000639:trends; D006801:Humans; D015201:Meta-Analysis as Topic; D015337:Multicenter Studies as Topic; D009203:Myocardial Infarction / Q000453:epidemiology / Q000517:prevention & control; D017239:Paclitaxel / Q000008:administration & dosage / Q000627:therapeutic use; D062645:Percutaneous Coronary Intervention / Q000295:instrumentation* / Q000379:methods; D011108:Polymers / Q000737:chemistry; D011183:Postoperative Complications / Q000453:epidemiology; D020123:Sirolimus / Q000008:administration & dosage / Q000627:therapeutic use; D015912:Thrombolytic Therapy; D016896:Treatment Outcome
chemical_list: D001672:Biocompatible Materials; D011108:Polymers; D017239:Paclitaxel; D020123:Sirolimus